217 related articles for article (PubMed ID: 28403575)
1. Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.
Alver SK; Lorenz DJ; Washburn K; Marvin MR; Brock GN
Transpl Int; 2017 Nov; 30(11):1098-1109. PubMed ID: 28403575
[TBL] [Abstract][Full Text] [Related]
2. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
Alver SK; Lorenz DJ; Marvin MR; Brock GN
Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
[TBL] [Abstract][Full Text] [Related]
3. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
4. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
5. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
6. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
[TBL] [Abstract][Full Text] [Related]
7. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
8. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
[TBL] [Abstract][Full Text] [Related]
9. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
10. Liver transplantation for hepatocellular carcinoma: the MELD impact.
Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
[TBL] [Abstract][Full Text] [Related]
11. Use of rapid Model for End-Stage Liver Disease (MELD) increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ Sharing.
Brock GN; Washburn K; Marvin MR
PLoS One; 2019; 14(10):e0223053. PubMed ID: 31581270
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
13. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
[TBL] [Abstract][Full Text] [Related]
14. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
[TBL] [Abstract][Full Text] [Related]
15. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
[TBL] [Abstract][Full Text] [Related]
16. Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Gorgen A; Rosales R; Sadler E; Beecroft R; Knox J; Dawson LA; Ghanekar A; Grant D; Greig PD; Sapisochin G
Transplantation; 2019 Oct; 103(10):2136-2143. PubMed ID: 30801510
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma.
Park SJ; Freise CE; Hirose R; Kerlan RK; Yao FY; Roberts JP; Vagefi PA
Clin Transplant; 2012; 26(4):E359-64. PubMed ID: 22693962
[TBL] [Abstract][Full Text] [Related]
18. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
[TBL] [Abstract][Full Text] [Related]
19. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
Mehta N; Dodge JL; Roberts JP; Hirose R; Yao FY
Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28881064
[TBL] [Abstract][Full Text] [Related]
20. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
